The Prime Minister’s office recently announced that Propath, a specialist in molecular pathology for biopharmaceutical research and development, is to receive a Queen’s Award for Enterprise in recognition of the company’s exceptional contribution to the UK’s Life Sciences sector.

As the UK’s most prestigious business accolade, the Queen’s Award is presented to those companies that demonstrate outstanding growth and achievement in business. Propath was selected to receive the award based on its contribution to the advancement of novel immunotherapies, and success in delivering specialist research services to the global biopharmaceutical sector.

Read more+



For confidential advice on your specific project, please feel free to contact us.



Pharmaceutical research demands the highest level of scientic rigour and focus on the smallest of details. And for 35 years, Propath has been doing just that: conducting GLP and GCP regulated research studies on behalf of its clients – focusing meticulously on every detail, whilst our experienced and committed scientists apply ever more innovative research techniques to generate reliable study outcomes.

In that time, many of our clients have pioneered innovative new therapies, especially in the promising field of immuno-oncology – which in turn have improved the quality of patients’ lives worldwide. Sponsors have made increasing demands on our services while regulatory requirements have become ever more exacting.

Propath has responded by building a team of highly motivated scientists and technicians, developing a culture of accuracy and QA compliance, and investing in the most advanced analytical technologies available. We have developed a vision of the service that matches our clients’ ambitions to be at the forefront of advances in novel therapies... and delivered that vision.

Today, Propath is one of Europe’s leading specialists in molecular pathology for biopharmaceutical research and development.

We are trusted by some of the world’s best-known bio-pharmaceutical businesses, as well as a host of spin offs and SMEs pioneering exciting new developments. They look to us to deliver robust results – rapidly and cost effectively. Our rigorous attention to the minutest detail ensures total compliance and consistent outcomes – every time.

Thousands of successfully conducted studies have demonstrated our professionalism and our commitment to clients. And our vision for the future will ensure that Propath will continue to be the very best at what we do.


Case study 1.0
Immunohistochemistry and quantitative digital image analysis

Acetyl Histone H3 showing (A) magnified area within original IHC image and (B) detection of Acetyl Histone H3 positive nuclei [cell classification overlay: negative (blue), low (yellow), medium (orange) or high (red)]. 

PD-L1, MHC-1, Acetyl-Histone H3 and Acetyl-α-Tubulin
UK based biotechnology company focussed on immuno-oncology
GLP/GCP status:

The aim of this study was to utilise IHC and quantitative digital image analysis techniques to evaluate expression of PD-L1, MHC-1, Acetyl Histone H3 and Acetyl-α-Tubulin within the viable tumour region of mouse syngeneic cell line derived xenograft tumour tissue samples. Read more

Case study 2.0
Multiplex / Dual marker IHC staining

FoxP3 (DAB/brown) and CD4 (red) multiplex IHC stain in Human tonsil tissue 

FoxP3 and CD4
Biotechnology company based in Israel
GLP/GCP status:

Scientists at Propath were asked to develop and optimise a dual IHC stain for immune cell markers FoxP3 and CD4 in human tonsil tissue, that could subsequently be used on human samples from a clinical trial. Multiplex stains are technically complex where multiple parameters require balancing to produce a clear, precise and intense stain for the two or more test articles. Read more

Case study 3.0
Therapeutic antibody tissue cross reactivity assessment

Acetyl Histone H3 showing (A) magnified area within original IHC image and (B) detection of Acetyl Histone H3 positive nuclei [cell classification overlay: negative (blue), low (yellow), medium (orange) or high (red)]. 

Test article structure:
Antibody-drug conjugate (ADC)
Swiss pharmaceutical company
GLP/GCP status:

The objective of this GLP tissue cross reactivity (TCR) study was to assess the potential cross reactivity of a novel antibody-drug conjugate in a panel of frozen human tissues and blood smears from three unrelated donors. Propath adopted a two-phase approach to this study: a non-GLP method development and validation phase to produce a robust, reliable immunohistochemical (IHC) method; followed by GLP staining and pathology review of the stained tissue panel. Read more